Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/118926
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: NAV-KIDS² trial: protocol for a multi-centre, staggered randomised controlled trial of a patient navigator intervention in children with chronic kidney disease
Other Titles: NAV-KIDS(2) trial: protocol for a multi-centre, staggered randomised controlled trial of a patient navigator intervention in children with chronic kidney disease
Author: van Zwieten, A.
Caldwell, P.
Howard, K.
Tong, A.
Craig, J.C.
Alexander, S.
Howell, M.
Armando, T.-.P.
Hawley, C.
Jesudason, S.
Walker, A.
Mackie, F.
Kennedy, S.
McTaggart, S.
McCarthy, H.
Carter, S.
Kim, S.
Crafter, S.
Woodleigh, R.
Guha, C.
et al.
Citation: BMC Nephrology, 2019; 20(1):134-1-134-9
Publisher: BioMed Central
Issue Date: 2019
ISSN: 1471-2369
1471-2369
Statement of
Responsibility: 
Anita van Zwieten, Patrina Caldwell, Kirsten Howard, Allison Tong, Jonathan C. Craig ... Shilpa Jesudason ... et al.
Abstract: BACKGROUND:Chronic kidney disease (CKD) is a devastating illness associated with increased mortality, reduced quality of life, impaired growth, neurocognitive impairment and psychosocial maladjustment in children. There is growing evidence of socioeconomic disparities in health outcomes among children with CKD. Patient navigators are trained non-medical personnel who assist patients with chronic conditions journey through the continuum of care and transit across different care settings. They help vulnerable and underserved populations to better understand their diagnosis, treatment options, and available resources, guide them through complex medical systems, and help them to overcome barriers to health care access. Given the complexity and chronicity of the disease process and concerns that current models of care may not adequately support the provision of high-level care in children with CKD from socioeconomically disadvantaged backgrounds, a patient navigator program may improve the provision of care and overall health of children with CKD. METHODS:The NAV-KIDS2 trial is a multi-centre, staggered entry, waitlisted randomised controlled trial assessing the health benefits and costs of a patient navigator program in children with CKD (stages 3-5, on dialysis, and with kidney transplants), who are of low socioeconomic backgrounds. Across 5 sites, 210 patients aged from 3 to 17 years will be randomised to immediate receipt of a patient navigator intervention for 24 weeks or waitlisting with standard care until receipt of a patient navigator at 24 weeks. The primary outcome is child self-rated health (SRH) 6-months after completion of the intervention. Other outcomes include utility-based quality of life, caregiver SRH, satisfaction with healthcare, progression of kidney dysfunction, other biomarkers, missed school days, hospitalisations and mortality. The trial also includes an economic evaluation and process evaluation, which will assess the cost-effectiveness, fidelity and barriers and enablers of implementing a patient navigator program in this setting. DISCUSSION:This study will provide clear evidence on the effectiveness and cost-effectiveness of a new intervention aiming to improve overall health and well-being for children with CKD from socioeconomically disadvantaged backgrounds, through a high quality, well-powered clinical trial. TRIAL REGISTRATION:Prospectively registered (12/07/2018) on the Australian New Zealand Clinical Trials Registry ( ACTRN12618001152213 ).
Keywords: Adolescents; Children; Chronic kidney disease; Dialysis; Health disparities; Kidney transplantation; Patient navigator; Randomised controlled trial; Socioeconomic disadvantage
Rights: © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
RMID: 0030113270
DOI: 10.1186/s12882-019-1325-y
Grant ID: http://purl.org/au-research/grants/nhmrc/1170021
http://purl.org/au-research/grants/nhmrc/1115259
http://purl.org/au-research/grants/nhmrc/1168994
http://purl.org/au-research/grants/nhmrc/1147657
http://purl.org/au-research/grants/nhmrc/1106716
http://purl.org/au-research/grants/nhmrc/1092957
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_118926.pdfPublished version720.47 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.